Vectors Research Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.12M Hold
4,267
1.34% 22
2026
Q1
$3.92M Buy
4,267
+7
+0.2% +$7.1K 1.15% 26
2025
Q4
$4.58M Buy
4,260
+1
+0% +$956 1.4% 19
2025
Q3
$3.25M Hold
4,259
1.02% 28
2025
Q2
$3.32M Hold
4,259
1.14% 24
2025
Q1
$3.52M Sell
4,259
-65
-2% -$54.1K 1.23% 22
2024
Q4
$3.34M Hold
4,324
1.14% 26
2024
Q3
$3.84M Hold
4,324
1.16% 23
2024
Q2
$3.92M Sell
4,324
-9
-0.2% -$7.2K 1.2% 22
2024
Q1
$3.37M Sell
4,333
-135,617
-97% -$96.5M 0.95% 27
2023
Q4
$2.47M Buy
139,950
+135,535
+3,070% +$79.1M 0.7% 39
2023
Q3
$2.37M Sell
4,415
-25
-0.6% -$12.9K 0.77% 32
2023
Q2
$2.08M Sell
4,440
-26
-0.6% -$10.9K 0.59% 47
2023
Q1
$1.53M Sell
4,466
-200
-4% -$67.5K 0.4% 62
2022
Q4
$1.71M Hold
4,666
0.44% 59
2022
Q3
$1.51M Hold
4,666
0.43% 59
2022
Q2
$1.51M Hold
4,666
0.38% 65
2022
Q1
$1.34M Hold
4,666
0.29% 77
2021
Q4
$1.29M Buy
4,666
+36
+0.8% +$9.13K 0.27% 76
2021
Q3
$1.07M Hold
4,630
0.25% 82
2021
Q2
$1.06M Hold
4,630
0.27% 83
2021
Q1
$865K Hold
4,630
0.24% 85
2020
Q4
$782K Buy
4,630
+550
+13% +$82.1K 0.24% 81
2020
Q3
$604K Buy
4,080
+100
+3% +$15.5K 0.22% 82
2020
Q2
$653K Hold
3,980
0.26% 74
2020
Q1
$552K Hold
3,980
0.26% 66
2019
Q4
$523K Hold
3,980
0.21% 74
2019
Q3
$445K Hold
3,980
0.22% 76
2019
Q2
$441K Hold
3,980
0.24% 73
2019
Q1
$516K Buy
+3,980
New +$484K 0.29% 67
2018
Q4
Sell
-3,980
Closed -$342K 700
2018
Q3
$342K Buy
+3,980
New +$398K 0.21% 80

Other funds holding LLY

Vectors Research Management's LLY Position: Q2 2026 in Review

Vectors Research Management held its Eli Lilly (LLY) position steady in Q2 2026 at 4,267 shares worth $5.12M. The position accounts for 1.34% of the portfolio, ranked #22.

Vectors Research Management first reported a position in LLY in Q3 2018 and has held it in 31 quarters since. 4,602 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Vectors Research Management held 4,267 shares of Eli Lilly worth $5.12M as of Q2 2026.
  • Vectors Research Management left its Eli Lilly share count unchanged in Q2 2026.
  • Eli Lilly made up 1.34% of Vectors Research Management's portfolio in Q2 2026, its #22 holding.
  • Vectors Research Management first reported a position in Eli Lilly in Q3 2018 and has held it in 31 quarters since.
  • 4,602 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Vectors Research Management's 13F filing for Q2 2026, filed 29 Jul 2026.